CE mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver PTX drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for what Cook Medical says is the world’s first and only approved drug-eluting stent for the superficial femoral artery.
In mid-January, a patient called me from her pharmacy, frantic. Her asthma inhalers came to $168 — a sum that she hadn’t been prepared for. But she can’t live without those inhalers, so she withdrew cash from her meager savings account and skipped her blood pressure pills for that month.
CryoLife has provided an update on its ongoing litigation with CR Bard and some of its subsidiaries regarding PerClot. The US District Court for the District of Delaware has allowed CryoLife’s declaratory judgement lawsuit against CR Bard’s Medafor subsidiary to proceed. The court also granted Medafor’s motion for a preliminary injunction with respect to CryoLife’s marketing and sale of PerClot Topical in the USA. CryoLife is currently awaiting the court’s order, which it expects will provide details regarding the scope of the injunction.
Medicare approves transitional pass-through payment for outpatient use of Medtronic’s drug-coated balloon Medtronic plc has announced that the US Centers for Medicare and Medicaid Services has approved a transitional pass-through payment for the company’s IN.PACT Admiral drug-coated balloon under the Medicare hospital outpatient prospective payment system, removing a potential barrier to patient access to this new medical device, which may represent a significant improvement to the standard of care for peripheral arterial disease in the upper leg.
Royal Philips has completed the acquisition of Volcano Corporation. Volcano’s financial results will be consolidated as part of Philips’ image-guided therapy business group as of 17 February, 2015.
Distal Access has announced the US Food and Drug Administration (FDA) clearance of the Spinr high-performance Guidewire Controller for use in the coronary and peripheral vasculature.
The ROX CONTROL HTN, an international randomised controlled trial, published online ahead of print in The Lancet in late January, has demonstrated that creation of a central arteriovenous anastomosis in patients was associated with significantly reduced blood pressure and hypertensive complications at six months. The study was funded by Rox Medical.
Vascular Flow Technologies has announced the start of a randomised controlled clinical trial at St Georges Hospital, London, UK.
Stentys’ drug-eluting and self-expanding stent was evaluated in 70 patients suffering from critical limb ischemia and prevented foot amputation in 99% of them.
When retrievable inferior vena cava filters were approved for use in the USA in 2003 to prevent pulmonary embolism among patients unable to receive the standard blood thinner treatment, many experts anticipated most of them would be removed when no longer needed and inferior vena cava filter complications would decrease.
Vascular Flow has announced the start of a randomised controlled clinical trial at St. George’s Hospital, London, UK.
TVA Medical has won the 2014 Innovations in Cardiovascular Interventions (ICI) Best Start-Up Innovation Award. The company received the honour for its everlinQ System, a catheter-based technology designed to create haemodialysis access for chronic kidney disease patients in a minimally-invasive procedure.
Veniti has announced the first use of the Vici venous stent system in Germany. The system is used to treat venous outflow obstruction in the lower extremities. The procedures were performed by Michael Lichtenberg, head of Interventional Angiology, Klinikum Arnsberg, Arnsberg, Germany.
According to the results of a new survey, the majority of interventionalists believe that the European community was “too quick” to start using renal denervation before the efficacy of the procedure was known. Furthermore, there has been a marked drop in the number of renal denervation procedures performed at European centres during 2014.
Covidien has announced that it has received CE mark approval for its Stellarex drug-coated angioplasty balloon. The Stellarex drug-coated angioplasty balloon is used to restore and maintain blood flow to the arteries of the leg in patients with peripheral arterial disease.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos